Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke

24.02.2005


Study in New England Journal of Medicine finds treatment significantly reduces bleeding in brain, decreases mortality by nearly 40% and reduces long-term disability for most deadly, least treatable form of stroke

A new multi-center, international study led by Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia shows that recombinant activated factor VII (rFVIIa) has the potential to be a significant advance in treating bleeding stroke (acute intracerebral hemorrhage or ICH). Published in the New England Journal of Medicine (Feb. 24 issue), the study found a reduction in hematoma growth (bleeding in the brain), decreased mortality, and improvement in neurological and clinical outcomes in patients treated with rFVIIa compared to placebo.

ICH is the deadliest and most disabling type of stroke – more than one out of three ICH patients die within one month of onset and only 20% regain functional independence. Physicians have long been frustrated by a lack of effective therapies to improve survival outcomes or recovery – current options are only supportive. RFVIIa is currently entering phase III trials as an investigational treatment for ICH. If approved by the U.S. Food and Drug Administration, it will become only the second emergency treatment for stroke in more than three decades – the first was TPA, approved by the FDA in 1996.



"Current medical and surgical options for ICH are not effective. Thirty-five to 50 percent of patients die within one month and if they survive, they live with serious neurological deficits. Current data suggest a possible change in our paradigm for the treatment of ICH," said Stephan A. Mayer, M.D., principal investigator of the study. Dr. Mayer is an associate professor of neurology and neurosurgery at Columbia University College of Physicians and Surgeons, and director of the Neurological Intensive Care Unit at NewYork-Presbyterian Hospital/Columbia.

"I approached this study with modest expectations, expecting to see some trends toward improved outcomes," noted Dr. Mayer. "I was stunned to find that by preventing just 5 ml of additional blood – about one teaspoon – of bleeding in the brain, we were able to increase chances of patient survival by nearly 40%." The third highest cause of death in the United States, stroke is the leading source of permanent disability – resulting in significant worsening of quality of life for patients and costing billions of dollars to society. ICH affects 15% of all stroke victims in the U.S., about 70,000 cases a year. In other parts of the world the incidence of bleeding stroke is even higher--in Asia, ICH affects 30% of all stroke victims.

With 73 sites in 20 countries, this study represents the largest clinical trial ever conducted with a pharmacologic agent for the treatment of ICH. As a physician treating patients over many years with this deadly form of stroke, Dr. Mayer decided to investigate rFVIIa as a treatment for ICH after reading about its coagulation effects. With the brand name NovoSeven®, rFVIIa has been on the U.S. market since 1999 as a treatment for hemophilia, and is manufactured by Novo Nordisk®.

Preliminary results of this trial were initially presented at the Fifth World Stroke Congress in Vancouver, B.C. in June 2004 and, most recently, at the International Stroke Conference in New Orleans in February 2005.

Study Results

The trial included 399 patients who all underwent a CT scan to confirm they had ICH within three hours of onset. Patients were randomly assigned to receive placebo (N=96), 40 (N=108), 80 (N=92), or 160 (N=103) µg/kg doses of rFVIIa within one hour of the baseline scan. The trial results showed that treatment of ICH with rFVIIa within four hours of symptom onset reduced mortality and improved three-month clinical outcome, along with the reduction in hematoma growth, despite a greater frequency of thromboembolic events.

The primary endpoint of the study was to determine if recombinant activated factor VII (rFVIIa) could reduce hematoma growth after ICH. The primary outcome measure was the percent change in ICH volume at 24 hours. Clinical outcomes were assessed at 90 days. Key findings include:

  • After dosing, the size of bleeding in the brain was assessed via CT scan within the first day and again three days later. Results found that overall, rFVIIa-treated patients had approximately half the amount of additional bleeding in the brain compared to placebo-treated patients.
  • ICH volume growth in the 40, 80, and 160 µg/kg treatment groups (P=0.01, rFVIIa vs. placebo) was reduced by 45%, 52% and 62% compared to the placebo treatment group.
  • After 90 days, results found a 38% reduction in mortality and up to three times as many patients surviving with no major neurological deficits, compared to placebo.
  • The proportion of patients treated with the 160 µg/kg dose of rFVIIa with no disability was 24%, compared to 8% in placebo.
  • Also after 90 days, there was a 16% absolute reduction in cases of death or severe disability among the rFVIIa treated patients.
  • This indicates that for approximately every six patients treated, one case of death or severe disability was avoided.
  • Safety endpoint: The overall frequency of fatal or disabling thromboembolic serious adverse events did not differ between the rFVIIa (2%) and the placebo (2%) groups. However, arterial thromboembolic serious adverse events occurred statistically significantly more frequently with rFVIIa treatment (5%) than with placebo (0%), manifesting in the form of myocardial ischemic events and cerebral infarction. The majority of patients recovered from these complications.

Columbia University Medical Center’s Department of Neurology is one of the largest in the country, and is internationally recognized for pioneering research in the development of new treatment modalities and protocols for stroke. Columbia researchers recently won a highly competitive $12 million stroke center grant from the NIH. Columbia is the first site in the eastern United States to receive this Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS) grant. Extending over five years, the funding will support three new research projects: one of the first clinical trials of statin medications as a potential stroke treatment; an imaging study of brain reorganization caused by stroke; and a novel stroke educational and behavior modification program.

Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, medical education, and health care. The medical center trains future leaders in health care and includes the dedicated work of many physicians, scientists, nurses, dentists, and other health professionals at the College of Physicians & Surgeons, the School of Dental & Oral Surgery, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. With a strong history of some of the most important advances and discoveries in health care, its researchers are leading the development of novel therapies and advances to address a wide range of health conditions.

Elizabeth Streich | EurekAlert!
Further information:
http://www.columbia.edu

More articles from Studies and Analyses:

nachricht Amputees can learn to control a robotic arm with their minds
28.11.2017 | University of Chicago Medical Center

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>